Strong Tower Advisory Services Buys 16,851 Shares of Solventum Corporation $SOLV

Strong Tower Advisory Services raised its stake in shares of Solventum Corporation (NYSE:SOLV) by 20.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 99,169 shares of the company’s stock after purchasing an additional 16,851 shares during the period. Solventum accounts for 1.4% of Strong Tower Advisory Services’ portfolio, making the stock its 26th largest holding. Strong Tower Advisory Services owned 0.06% of Solventum worth $7,239,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the company. Independent Franchise Partners LLP boosted its holdings in Solventum by 74.2% during the second quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company’s stock valued at $769,098,000 after acquiring an additional 4,320,342 shares during the period. Davis Selected Advisers increased its position in Solventum by 3.9% during the second quarter. Davis Selected Advisers now owns 5,492,661 shares of the company’s stock worth $416,563,000 after acquiring an additional 204,523 shares during the period. Boston Partners boosted its holdings in Solventum by 9.2% in the 2nd quarter. Boston Partners now owns 3,670,757 shares of the company’s stock valued at $278,363,000 after purchasing an additional 308,784 shares during the period. Geode Capital Management LLC boosted its holdings in Solventum by 1.0% in the 2nd quarter. Geode Capital Management LLC now owns 3,563,792 shares of the company’s stock valued at $269,116,000 after purchasing an additional 36,660 shares during the period. Finally, Norges Bank bought a new position in shares of Solventum during the 2nd quarter worth about $140,495,000.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several research reports. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Jefferies Financial Group assumed coverage on Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 price target on the stock. Finally, Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Solventum presently has an average rating of “Hold” and a consensus target price of $87.00.

Solventum Stock Down 0.4%

SOLV stock opened at $80.46 on Wednesday. The business has a 50-day moving average of $77.22 and a 200-day moving average of $74.75. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $88.20. The stock has a market capitalization of $13.96 billion, a P/E ratio of 9.27, a P/E/G ratio of 8.53 and a beta of 0.26. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same period last year, the company earned $1.64 earnings per share. The firm’s revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, sell-side analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its Board of Directors has approved a share repurchase plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to buy up to 7.5% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.